Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Cancers, Free Full-Text

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations

Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer

Prostate cancer: The hunt for a silver bullet - Medical Independent

Rucaparib improves radiographic PFS in prostate cancer subgroup

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association

Rucaparib Bests Physician's Choice for BRCA+ mCRPC

Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study - European Journal of Cancer